GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sana Biotechnology Inc (NAS:SANA) » Definitions » PE Ratio without NRI

SANA (Sana Biotechnology) PE Ratio without NRI : At Loss (As of Nov. 10, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sana Biotechnology PE Ratio without NRI?

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2024-11-10), Sana Biotechnology's share price is $3.005. Sana Biotechnology's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was $-1.15. Therefore, Sana Biotechnology's PE Ratio without NRI for today is At Loss.

Sana Biotechnology's EPS without NRI for the three months ended in Jun. 2024 was $-0.21. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was $-1.15.

As of today (2024-11-10), Sana Biotechnology's share price is $3.005. Sana Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $-1.15. Therefore, Sana Biotechnology's PE Ratio (TTM) for today is At Loss.

Sana Biotechnology's EPS (Diluted) for the three months ended in Jun. 2024 was $-0.21. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $-1.15.

Sana Biotechnology's EPS (Basic) for the three months ended in Jun. 2024 was $-0.21. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was $-1.15.


Sana Biotechnology PE Ratio without NRI Historical Data

The historical data trend for Sana Biotechnology's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sana Biotechnology PE Ratio without NRI Chart

Sana Biotechnology Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio without NRI
Get a 7-Day Free Trial N/A N/A At Loss At Loss At Loss

Sana Biotechnology Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of Sana Biotechnology's PE Ratio without NRI

For the Biotechnology subindustry, Sana Biotechnology's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sana Biotechnology's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sana Biotechnology's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Sana Biotechnology's PE Ratio without NRI falls into.



Sana Biotechnology PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Sana Biotechnology's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=3.005/-1.145
=-2.62(At Loss)

Sana Biotechnology's Share Price of today is $3.005.
Sana Biotechnology's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.15.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Sana Biotechnology  (NAS:SANA) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Sana Biotechnology PE Ratio without NRI Related Terms

Thank you for viewing the detailed overview of Sana Biotechnology's PE Ratio without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Sana Biotechnology Business Description

Traded in Other Exchanges
N/A
Address
188 East Blaine Street, Suite 400, Seattle, WA, USA, 98102
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others.
Executives
Patrick Y Yang director C/O GENENTECH INC, 1 DNA WAY,MS 49,ATTN:K.STRAND OR J.BERRY, SOUTH SAN FRANCISCO CA 94080-4990
Keith Crandell 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Robert Nelsen director 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund X Overage, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Christian Hordo officer: SVP, Chief Business Officer C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 400, SEATTLE WA 98102
Flagship Ventures Fund V, L.p. 10 percent owner ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142
Douglas E Williams officer: EVP & President, R&D C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Bernard J Cassidy officer: EVP & General Counsel C/O TUMBLEWEED COMMUNICATIONS CORP, 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
James J. Macdonald officer: See Remarks C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 400, SEATTLE WA 98102
Sunil Agarwal officer: See Remarks 60 LEVERONI COURT, NOVATO CA 94949
Flagship Venturelabs V Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Venturelabs V Manager Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Arch Venture Fund Ix, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund Ix Overage, L.p. 10 percent owner 8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631
Arch Venture Partners Ix, Llc 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631